As the number of patients afflicted by chronic limb-threatening ischemia (CLTI) continues to grow, new solutions are necessary to provide effective, durable treatment options that will lead to improved outcomes. The diagnosis of CLTI remains mostly clinical, and endovascular revascularization remains mostly balloon-based. Multiple innovative techniques and technologies are in development or in early usage that may provide new solutions. This review categorizes areas of advancement, highlights recent developments in the management of CLTI and looks forward to novel devices that are currently under investigation.
ConteMSBradburyAWKolhP, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6S):3S–125S.e40.
2.
DuffSMafiliosMSBhounsuleP, et al. The burden of critical limb ischemia: a review of recent literature. Vasc Health Risk Manag. 2019;15:187–208.
3.
UccioliLMeloniMIzzoV, et al. Critical limb ischemia: current challenges and future prospects. Vasc Health Risk Manag. 2018;14:63–74.
MustaphaJAKatzenBTNevilleRF, et al. Determinants of long-term outcomes and costs in the management of critical limb ischemia: a population-based cohort study. J Am Heart Assoc. 2018;7(16):e009724.
6.
MillsJLConteMSArmstrongDG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1):220–234.e2.
7.
LairdJRSchneiderPATepeG, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.
8.
WeaverMLHicksCWCannerJK, et al. The Society for Vascular Surgery wound, ischemia, and foot infection (WIfI) classification system predicts wound healing better than direct angiosome perfusion in diabetic foot wounds. J Vasc Surg. 2018;68:1473–1481.
9.
DarlingJDMcCallumJCSodenPA, et al. Predictive ability of the SVS WIfI classification system following first-time lower extremity revascularizations. J Vasc Surg. 2017;65:695–704.
10.
RobinsonWPLoretzLHanesianC, et al. Society for Vascular Surgery wound, ischemia, foot infection (WIfI) score correlates with the intensity of multimodal limb treatment and patient-centered outcomes in patients with threatened limbs managed in a limb preservation center. J Vasc Surg. 2017;66:488–498.e2.
11.
CauseyMWAhmedAWuB, et al. Society for Vascular Surgery limb stage and patient risk correlate with outcomes in an amputation prevention program. J Vasc Surg. 2016;63(6):1563–1573.e2.
12.
DarlingJDMcCallumJCSodenPA, et al. Predictive ability of the Society for Vascular Surgery wound, ischemia, and foot infection (WIfI) classification system following infrapopliteal endovascular interventions for critical limb ischemia. J Vasc Surg. 2016;64:616–622.
13.
TreimanGSOderichGSAshrafiA, et al. Management of ischemic heel ulceration and gangrene: An evaluation of factors associated with successful healing. J Vasc Surg. 2000;31:1110–1118.
14.
NewmanMISamsonMC.The application of laser-assisted indocyanine green fluorescent dye angiography in microsurgical breast reconstruction. J Reconstr Microsurg. 2009;25:21–26.
15.
GurtnerGCJonesGENeliganPC, et al. Intraoperative laser angiography using the SPY system: review of the literature and recommendations for use. Ann Surg Innov Res. 2013;7:1. doi:10.1186/1750-1164-7-1.
16.
ColvardBItogaNKHitchnerE, et al. SPY technology as an adjunctive measure for lower extremity perfusion. J Vasc Surg. 2016;64:195–201.
17.
IgariKKudoTToyofukuT, et al. Quantitative evaluation of the outcomes of revascularization procedures for peripheral arterial disease using indocyanine green angiography. Eur J Vasc Endovasc Surg. 2013;46:460–465.
18.
DupréeARießHDetterC, et al. Utilization of indocyanine green fluorescent imaging (ICG-FI) for the assessment of microperfusion in vascular medicine. Innov Surg Sci. 2018;3:193–201.
19.
BraunJDTrinidad-HernandezMPerryD, et al. Early quantitative evaluation of indocyanine green angiography in patients with critical limb ischemia. J Vasc Surg. 2013;57:1213–1218.
20.
ReekersJAKoelemayMJWMarqueringHA, et al. Functional Imaging of the foot with perfusion angiography in critical limb ischemia. Cardiovasc Intervent Radiol. 2016;39:183–189.
21.
YoneyamaFOsakaMSatoF, et al. Efficacy of two-dimensional perfusion angiography for evaluations after infrapopliteal bypass surgery for critical limb ischemia. Ann Vasc Dis. 2018;11:248–251.
22.
JensSMarqueringHAKoelemayMJW, et al. Perfusion angiography of the foot in patients with critical limb ischemia: description of the technique. Cardiovasc Intervent Radiol. 2015;38:201–205.
23.
HinrichsJBMurrayTAkinM, et al. Evaluation of a novel 2D perfusion angiography technique independent of pump injections for assessment of interventional treatment of peripheral vascular disease. Int J Cardiovasc Imaging. 2017;33:295–301.
24.
MurrayTRodtTLeeMJ.Two-dimensional perfusion angiography of the foot: technical considerations and initial analysis. J Endovasc Ther. 2016;23:58–64.
25.
KimAHShevitzAJMorrowKL, et al. Characterizing tissue perfusion after lower extremity intervention using two-dimensional color-coded digital subtraction angiography. J Vasc Surg. 2017;66:1464–1472.
26.
DraijerMHondebrinkEvan LeeuwenT, et al. Review of laser speckle contrast techniques for visualizing tissue perfusion. Lasers Med Sci. 2009;24:639–651.
27.
KleissSFMaKFSchuurmannRC, et al. Hyperspectral imaging for noninvasive tissue perfusion measurements of the lower leg: review of literature and introduction of a standardized measurement protocol with a portable system. J Cardiovasc Surg (Torino). 2019;60:652–661.
28.
NouvongAHoogwerfBMohlerE, et al. Evaluation of diabetic foot ulcer healing with hyperspectral imaging of oxyhemoglobin and deoxyhemoglobin. Diabetes Care. 2009;32:2056–2061.
29.
Montero-BakerMFAu-YeungKYWisniewskiNA, et al. The first-in-man “Si Se Puede” study for the use of micro-oxygen sensors (MOXYs) to determine dynamic relative oxygen indices in the feet of patients with limb-threatening ischemia during endovascular therapy. J Vasc Surg. 2015;61:1501–1510.e1.
30.
ChenXAssadsangabiBHsiangY, et al. Enabling angioplasty-ready “smart” stents to detect in-stent restenosis and occlusion. Adv Sci. 2018;5:1700560.
31.
BussooaANealeSMercerJR.Future of smart cardiovascular implants. Sensors (Basel). 2018;18(7):2008. doi:10.3390/s18072008.
32.
OhkiTOurielKSilveiraPG, et al. Initial results of wireless pressure sensing for endovascular aneurysm repair: The APEX Trial—Acute Pressure Measurement to Confirm Aneurysm Sac EXclusion. J Vasc Surg. 2007;45:236–242.
33.
ParsaCJDaneshmandMALimaB, et al. Utility of remote wireless pressure sensing for endovascular leak detection after endovascular thoracic aneurysm repair. Ann Thorac Surg. 2010;89:446–452.
34.
NattaLMastronardiVMGuidoF, et al. Soft and flexible piezoelectric smart patch for vascular graft monitoring based on aluminum nitride thin film. Sci Rep. 2019;9:1–10.
35.
NevilleRFGuptaSKKuraguntlaDJ.Initial in vitro and in vivo evaluation of a self-monitoring prosthetic bypass graft. J Vasc Surg. 2017;65:1793–1801.
36.
ChangACDearmanBGreenwoodJE.A comparison of wound area measurement techniques: Visitrak versus photography. Eplasty. 2011;e18.
37.
YeeAHarmonJYiS.Quantitative monitoring wound healing status through three-dimensional imaging on mobile platforms. J Am Coll Clin Wound Spec. 2017;8:21–27.
38.
DarwinESJallerJAHirtPA, et al. Comparison of 3-dimensional wound measurement with laser-assisted and hand measurements: a retrospective chart review. Wound Manag Prev. 2019;65:36–41.
39.
TønnesenKHSagerPKarleA, et al. Percutaneous transluminal angioplasty of the superficial femoral artery by retrograde catheterization via the popliteal artery. Cardiovasc Intervent Radiol. 1988;11:127–131.
40.
WellingRHABakkerOJScheinertD, et al. Below-the-knee retrograde access for peripheral interventions: a systematic review. J Endovasc Ther. 2018;25:345–352.
41.
GürSOğuzkurtLGürelK, et al. US-guided retrograde tibial artery puncture for recanalization of complex infrainguinal arterial occlusions. Diagn Interv Radiol. 2013;19:134–140.
42.
BazanHAPradhanSMojibianH, et al. Increased aortic arch calcification in patients older than 75 years: implications for carotid artery stenting in elderly patients. J Vasc Surg. 2007;46:841–845.
43.
BazanHALeLDonovanM, et al. Retrograde pedal access for patients with critical limb ischemia. J Vasc Surg. 2014;60:375–381.
44.
SabriSSHendricksNStoneJ, et al. Retrograde pedal access technique for revascularization of infrainguinal arterial occlusive disease. J Vasc Interv Radiol. 2015;26:29–38.
45.
SchmidtABausbackYPiorkowskiM, et al. Retrograde tibioperoneal access for complex infrainguinal occlusions: short- and long-term outcomes of 554 endovascular interventions. JACC Cardiovasc Interv. 2019;12:1714–1726.
46.
SubramanianNXuJKassemLS, et al. Absent or diminished pedal pulses and estimated GFR decline in patients with diabetic kidney disease. Ren Fail. 2019;41:691–697.
47.
BaghdasaryanPABaeJHYuW, et al. “The renal foot”—Angiographic pattern of patients with chronic limb threatening ischemia and end-stage renal disease. Cardiovasc Revasc Med. 2020;21:118–121.
48.
HaineAHaynesAGLimacherA, et al. Patency of the arterial pedal-plantar arch in patients with chronic kidney disease or diabetes mellitus. Ther Adv Cardiovasc Dis. 2018;12:145–153.
49.
FusaroMDalla PaolaLBiondi-ZoccaiG.Pedal-plantar loop technique for a challenging below-the-knee chronic total occlusion: a novel approach to percutaneous revascularization in critical lower limb ischemia. J Invasive Cardiol. 2007;19:E34–E37.
50.
ManziMFusaroMCeccacciT, et al. Clinical results of below-the knee intervention using pedal-plantar loop technique for the revascularization of foot arteries. J Cardiovasc Surg (Torino). 2009;50:331–337.
51.
RashidHSlimHZayedH, et al. The impact of arterial pedal arch quality and angiosome revascularization on foot tissue loss healing and infrapopliteal bypass outcome. J Vasc Surg. 2013;57:1219–1226.
52.
DesaiTRMeyersonSLSkellyCL, et al. Patency and limb salvage after infrainguinal bypass with severely compromised (blind) outflow. Arch Surg. 2001;136:635–642.
53.
BiancariFAlbäckAIhlbergL, et al. Angiographic runoff score as a predictor of outcome following femorocrural bypass surgery. Eur J Vasc Endovasc Surg. 1999;17:480–485.
54.
FernandezNMcEnaneyRMaroneLK, et al. Predictors of failure and success of tibial interventions for critical limb ischemia. J Vasc Surg. 2010;52:834–842.
55.
TroisiNTuriniFChisciE, et al. Impact of pedal arch patency on tissue loss and time to healing in diabetic patients with foot wounds undergoing infrainguinal endovascular revascularization. Korean J Radiol. 2018;19:47–53.
56.
NakamaTWatanabeNHaraguchiT, et al. Clinical outcomes of pedal artery angioplasty for patients with ischemic wounds: results from the multicenter RENDEZVOUS registry. JACC Cardiovasc Interv. 2017;10:79–90.
57.
FitzgeraldPJPortsTAYockPG.Contribution of localized calcium deposits to dissection after angioplasty. An observational study using intravascular ultrasound. Circulation. 1992;86:64–70.
58.
GussenhovenEJZhongYLiW, et al. Effect of balloon angioplasty on femoral artery evaluated with intravascular ultrasound imaging. Circulation. 1992;86:483–493.
59.
GasserTCHolzapfelGA.Modeling plaque fissuring and dissection during balloon angioplasty intervention. Ann Biomed Eng. 2007;35:711–723.
60.
LosordoDWRosenfieldKPieczekA, et al. How does angioplasty work? Serial analysis of human iliac arteries using intravascular ultrasound. Circulation. 1992;86:1845–1858.
61.
TepeGZellerTSchnorrB, et al. High-grade, non-flow-limiting dissections do not negatively impact long-term outcome after paclitaxel-coated balloon angioplasty: an additional analysis from the THUNDER study. J Endovasc Ther. 2013;20:792–800.
62.
KobayashiNHiranoKYamawakiM, et al. Simple classification and clinical outcomes of angiographic dissection after balloon angioplasty for femoropopliteal disease. J Vasc Surg. 2018;67:1151–1158.
63.
FujiharaMTakaharaMSasakiS, et al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease. J Endovasc Ther. 2017;24:367–375.
64.
HongS-JKoY-GShinD-H, et al. Outcomes of spot stenting versus long stenting after intentional subintimal approach for long chronic total occlusions of the femoropopliteal artery. JACC Cardiovasc Interv. 2015;8:472–480.
65.
BosiersMScheinertDHendriksJMH, et al. Results from the Tack Optimized Balloon Angioplasty (TOBA) study demonstrate the benefits of minimal metal implants for dissection repair after angioplasty. J Vasc Surg. 2016;64:109–116.
66.
SchneiderPAGiasolliREbnerA, et al. Early experimental and clinical experience with a focal implant for lower extremity post-angioplasty dissection. JACC Cardiovasc Interv. 2015;8:347–354.
67.
GrayWACardenasJABrodmannM, et al. Treating post-angioplasty dissection in the femoropopliteal arteries using the Tack Endovascular System: 12-month results from the TOBA II study. JACC Cardiovasc Interv. 2019;12:2375–2384.
68.
BrodmannMWissgottCHoldenA, et al. Treatment of infrapopliteal post-PTA dissection with tack implants: 12-month results from the TOBA-BTK study. Catheter Cardiovasc Interv. 2018;92:96–105.
69.
AdamsG.6-Month results of TOBA II BTK. Paper presented at: VIVA; November 6, 2019; Las Vegas, NV, USA.
70.
SilingardiRLauricellaACoppiG, et al. Durability and efficacy of tibial arterial stent placement for critical limb ischemia. J Vasc Interv Radiol. 2015;26:475–483.e2.
71.
TrombertDCaraduCBrizziV, et al. Evidence for the use of drug eluting stents in below-the-knee lesions. J Cardiovasc Surg (Torino). 2015;56:67–71.
72.
Rocha-SinghKJJaffMRCrabtreeTR, et al; VIVA Physicians, Inc. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv. 2007;69:910–919.
73.
BosiersM.Is vessel prep necessary before treating the SFA?J Cardiovasc Surg (Torino). 2019;60:557–566.
74.
HoldenAHillAWalkerA, et al. PRELUDE prospective study of the Serranator device in the treatment of atherosclerotic lesions in the superficial femoral and popliteal arteries. J Endovasc Ther. 2019;26:18–25.
75.
BakkenAMPalchikEHartJP, et al. Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions. J Vasc Surg. 2007;46:946–958.
76.
LairdJRKatzenBTScheinertD, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267–276.
77.
TepeGBeschornerURuetherC, et al. Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium. J Endovasc Ther. 2015;22:727–733.
78.
FanelliFCannavaleAGazzettiM, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.
79.
IchihashiSShibataTFujimuraN, et al. Vessel calcification as a risk factor for in-stent restenosis in complex femoropopliteal lesions after Zilver PTX paclitaxel-coated stent placement. J Endovasc Ther. 2019;26:613–620.
80.
BrodmannMWernerMBrintonTJ, et al. Safety and performance of lithoplasty for treatment of calcified peripheral artery lesions. J Am Coll Cardiol. 2017;70:908–910.
81.
BrodmannMWernerMHoldenA, et al. Primary outcomes and mechanism of action of intravascular lithotripsy in calcified, femoropopliteal lesions: results of Disrupt PAD II. Catheter Cardiovasc Interv. 2019;93:335–342.
82.
BrodmannMHoldenAZellerT.Safety and feasibility of intravascular lithotripsy for treatment of below-the-knee arterial stenoses. J Endovasc Ther. 2018;25:499–503.
83.
DabrhAMASteffenMWUndavalliC, et al. The natural history of untreated severe or critical limb ischemia. J Vasc Surg. 2015;62:1642–1651.e3.
84.
SprengersRWTeraaMMollFL, et al. Quality of life in patients with no-option critical limb ischemia underlines the need for new effective treatment. J Vasc Surg. 2010;52:843–849.e1.
85.
SchreveMAVosCGVahlAC, et al. Venous arterialisation for salvage of critically ischaemic limbs: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2017;53:387–402.
86.
SchreveMAÜnlüÇKumS, et al. Surgical and endovascular venous arterialization: ready to take the “desert” by storm?J Cardiovasc Surg (Torino). 2017;58:402–408.
87.
SchreveMALichtenbergMÜnlüÇ, et al. PROMISE international; a clinical post marketing trial investigating the percutaneous deep vein arterialization (LimFlow) in the treatment of no-option chronic limb ischemia patient. CVIR Endovasc. 2019;2:26. doi:10.1186/s42155-019-0067-z.
88.
KumSTanYKSchreveMA, et al. Midterm outcomes from a pilot study of percutaneous deep vein arterialization for the treatment of no-option critical limb ischemia. J Endovasc Ther. 2017;24:619–626.
89.
MustaphaJASaabFAClairD, et al. Interim results of the PROMISE I trial to investigate the LimFlow system of percutaneous deep vein arterialization for the treatment of critical limb ischemia. J Invasive Cardiol. 2019;31:57–63.
90.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;18;7(24):e011245.
91.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischemia: a systematic review and meta-analysis of randomized controlled trials. J Vasc Interv Radiol. 2020;31:202–212.
92.
FreisingerEKoeppeJGerssJ, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis [published online October 8, 2019]. Eur Heart J. doi:10.1093/eurheartj/ehz698.
93.
SchneiderPALairdJRDorosG, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. J Am Coll Cardiol. 2019;73:2550–2563.
94.
KuminsNHKingAHAmbaniRN, et al. Paclitaxel-coated peripheral artery devices are not associated with increased mortality [published online January 6, 2020]. J Vasc Surg. doi:10.1016/j.jvs.2019.10.100.
95.
ShishehborMHSchneiderPAZellerT, et al. Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts. J Vasc Surg. 2019;70:1177–1191.e9.
96.
LairdJASchneiderPAJaffMR, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv. 2019;12(6):e007702.
97.
HoldenAVarcoeRLJaffMR, et al. Paclitaxel and mortality: the dose argument is critical. J Endovasc Ther. 2019;26:467–470.
98.
MillsJLConteMSMuradMH.Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery disease. J Vasc Surg. 2019;70:3–7.
SecemskyEAKundiHWeinbergI, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019;4:332–340.
101.
KolodgieFDPachecoEYahagiK, et al. Comparison of particulate embolization after femoral artery treatment with IN.PACT Admiral versus Lutonix 035 paclitaxel-coated balloons in healthy swine. J Vasc Interv Radiol2016;27:1676–1685.e2.
102.
ToriiSJinnouchiHSakamotoA, et al. Comparison of biologic effect and particulate embolization after femoral artery treatment with three drug-coated balloons in healthy swine model. J Vasc Interv Radiol. 2019;30:103–109.
103.
BoitetAGrassin-DelyleSLouedecL, et al. An experimental study of paclitaxel embolisation during drug coated balloon angioplasty. Eur J Vasc Endovasc Surg. 2019;57:578–586.
104.
ChaudhuriA.Are all DCBs created equal?Eur J Vasc Endovasc Surg. 2019;57:587.
105.
ZellerTBaumgartnerIScheinertD, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568–1576.
106.
ZellerTBeschornerUPilgerE, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK’S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8:1614–1622.
107.
MustaphaJABrodmannMGeraghtyPJ, et al. Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK trial. J Invasive Cardiol. 2019;31:205–211.
108.
TepeG.BIOLUX P-III Passeo-18 Lux all-comers registry: 24-month results for the full cohort. Paper presented at: LINC 2019; January 22, 2019; Leipzig, Germany.
109.
ZellerTLanghoffRRocha-SinghKJ, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv. 2017; 10(9):e004848. doi:10.1161/CIRCINTER-VENTIONS.116.004848.
110.
StavroulakisKSchwindtATorselloG, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther. 2017;24:181–188.
111.
CioppaAStabileEPopusoiG, et al. Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and a paclitaxel coated balloon: one-year single centre clinical results. Cardiovasc Revasc Med. 2012;13:219–223.
112.
TzafririARGarcia-PoliteFZaniB, et al. Calcified plaque modification alters local drug delivery in the treatment of peripheral atherosclerosis. J Control Release. 2017;264:203–210.
113.
ScheinertDKatsanosKZellerT, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60:2290–2295.
114.
BosiersMScheinertDPeetersP, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390–398.
115.
FortierAGullapalliVMirshamsRA.Review of biomechanical studies of arteries and their effect on stent performance. IJC Heart Vessels. 2014;4:12–18.
116.
OkamotoECouseTDe LeonH, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation. 2001;104:2228–2235.
117.
SchillingerMExnerMMlekuschW, et al. Balloon angioplasty and stent implantation induce a vascular inflammatory reaction. J Endovasc Ther. 2002;9:59–66.
118.
SchillingerMExnerMMlekuschW, et al. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. Radiology. 2002;224:529–535.
119.
OwensCDGasperWJWalkerJP, et al. Safety and feasibility of adjunctive dexamethasone infusion into the adventitia of the femoropopliteal artery following endovascular revascularization. J Vasc Surg. 2014;59:1016–1024.
120.
KaranianJWPeregoyJAChiesaOA, et al. Efficiency of drug delivery to the coronary arteries in swine is dependent on the route of administration: assessment of luminal, intimal, and adventitial coronary artery and venous delivery methods. J Vasc Interv Radiol. 2010;21:1555–1564.
SiowRCMMallawaarachchiCMWeissbergPL. Migration of adventitial myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries. Cardiovasc Res. 2003;59:212–221.
123.
PennMSEllisSGandhiS, et al. Adventitial delivery of an allogeneic bone marrow-derived adherent stem cell in acute myocardial infarction: phase I clinical study. Circ Res. 2012;110:304–311.
124.
RazaviMKDonohoeDD’AgostinoRB, et al. Adventitial drug delivery of dexamethasone to improve primary patency in the treatment of superficial femoral and popliteal artery disease: 12-month results from the DANCE clinical trial. JACC Cardiovasc Interv. 2018;11:921–931.
125.
NordmannAJBrielMBucherHC.Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784–2814.
126.
StoneGWEllisSGColomboA, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007;115:2842–2847.
127.
PalmeriniTBiondi-ZoccaiGDella RivaD, et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting?J Am Coll Cardiol. 2013;62:1915–1921.
128.
LammerJBosiersMZellerT, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg. 2011;54:394–401.
129.
DudaSHBosiersMLammerJ, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
130.
WesselyRSchömigAKastratiA.Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol. 2006;47:708–714.
131.
KolachalamaVBPacettiSDFransesJW, et al. Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy. Circulation. 2013;127:2047–2055.
132.
ElickerRJShulzeJEAhleringMT, et al. TCT-843 Preclinical evaluation of the SELUTIONTM sirolimus drug coated balloon in a porcine coronary overstretch model [abstract]. J Am Coll Cardiol. 2019;68(18 suppl):B340–B341.
133.
BrechtelKMeyerD-RAlbrechtT, et al. TCT-525 First report of the 12-month outcomes of SELUTION trial: a novel sirolimus coated DCB technology evaluated in SFA [abstract]. J Am Coll Cardiol. 2018;72(13 suppl):B211.
VarcoeRLSchoutenOThomasSD, et al. Initial experience with the Absorb Bioresorbable Vascular Scaffold below the knee: six-month clinical and imaging outcomes. J Endovasc Ther. 2015;22:226–232.
136.
VarcoeRLThomasSDLennoxAF.Three-year results of the Absorb everolimus-eluting bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2018;25:694–701.
137.
LammerJBosiersMDelooseK, et al. Bioresorbable everolimus-eluting vascular scaffold for patients with peripheral artery disease (ESPRIT I): 2-year clinical and imaging results. JACC Cardiovasc Interv. 2016;13;9:1178–1187.
